Scientific Studies

Scientifically validated in independent human intervention studies to support cardiometabolic health

We have published multiple clinical trials with leading UK universities and world-leading professors in microbiology to support the efficacy and safety of our patented probiotic strains and products.

¹ Safety and efficacy of LP_LDL^® in normal to mildly hypercholesterolemic adults

A 12-week, independent, double blind, randomised, placebo-controlled human intervention in 49 adults (total cholesterol at baseline between 5.16 and 7.64mM), taking 4×109CFU encapsulated LP_LDL^® or placebo. Results are based on 12 weeks consumption LP_LDL^® vs placebo.

LP_LDL^® was shown to be completely safe, well-tolerated and statistically significant to improve multiple cardiometabolic biomarkers:

² Efficacy of LP_LDL^® within a finished product formulation CholBiome_BP in pre-hypertensive adults

A 12-week independent, clinical study was carried out in 40 adults with high normal blood pressure (systolic blood pressure 130-139mm Hgm diastolic blood pressure 85-89mmg). Volunteers consumed 1 tablet of CholBiome_BP daily. Results are based on 12 weeks consumption vs baseline (pre-intervention levels).CholBiome_BP was shown to be statistically significant on improving multiple cardiometabolic biomarkers:

³ The cholesterol lowering efficacy of LP_LDL^® in hypercholesterolemic adults.

A 9-week, independent, double blind, randomised, placebo-controlled human intervention study in 16 adults taking 4×109CFU encapsulated LP_LDL^® or placebo. Results are based on 6 weeks consumption of LP_LDL^® vs placebo on a daily basis, followed by a 3-week washout period.

LP_LDL^® was shown to be completely safe, well-tolerated and showcased statistically significant reductions in multiple cardiometabolic biomarkers within 6 weeks: